Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing Of Claims:

WHAT IS CLAIMED IS:

1. A compound having the Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein:

Q_1 and Q_2 are independently =O, =S, =NH or =N-NHR, where R is -H, -C_1-C_{10} alkyl, or -aryl;

Q_3 is -O-, -S-, or -N(H)-;

R_1 and R_2 are independently -H, -halogen, -amino, -C_1-C_{10} alkyl, -C_1-C_{10} alkoxy, -C_1-C_{10} (hydroxy)alkyl, -C_1-C_{10} (amino)alkyl, -C_1-C_{10} (halo)alkyl, -C_2-C_{10} alkenyl, -C_2-C_{10} alkynyl, (C_3-C_7) cycloalkyl, -aryl, C_1-C_{10} (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R_1, R_2 and the carbon atom to which they are both attached are taken together to form a (C_3-C_7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;

A is N or CR_3; B is N or CR_4; D is N or CR_5; E is N or CR_6, at least one of A, B, D and E being CR_3, CR_4, CR_5 or CR_6, respectively;

each R_3, R_4, R_5 and R_6 is independently -H, -halogen, -CN, -NH_2, -NO_2,

-COOH, -C(O)NH_2, -SH, -S(O)NH_2, -S(O)$_2$$NH_2$, -$C_1$-$C_{10}$ (oxy)alkyl, -C_1-C_{10} alkyl, -C_1-C_{10} alkoxy, -C_1-C_{10} (hydroxy)alkyl, -C_1-C_{10} (amino)alkyl, -C_1-C_{10} (halo)alkyl, -C_2-C_{10} alkenyl, -

C_2-C_{10} alkynyl, -(C_3-C_7) cycloalkyl, -aryl, -C_1-C_{10} (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, -CH_2OR_{11}, -OCH_2OR_{11}, -$OC(O)R_{11}$, -$C(O)R_{11}$, -$OC(O)OR_{11}$, -$OC(O)NR_{11}$, -$C(O)OR_{11}$, -$C(O)NR_{11}$, -$OP(O)(OR_{11})_2$, -SR_{11}, -$S(O)_2NHR_{11}$, -SOR_{11}, -$S(O)_2R_{11}$, -$NHC(O)R_{11}$, -$NHSOR_{11}$, or $NHS(O)_2R_{11}$; or

R_3 and R_4 and the carbon atoms to which they are attached are taken together to form a (C_3-C_7) cycloalkenyl group, a five- to seven-membered non-aromatic heterocycle, or a five- to seven-membered aromatic heterocycle; or

R_5 and R_6 and the carbon atoms to which they are attached are taken together to form a (C_3-C_7) cycloalkenyl group, a five- to seven-membered non-aromatic heterocycle, or a five- to seven-membered aromatic heterocycle; or

R_4 and R_5 and the carbon atoms to which they are attached are taken together to form a (C_3-C_7) cycloalkenyl group, a non-oxygen-containing five-membered non-aromatic heterocycle, a non-oxygen-containing five-membered aromatic heterocycle, a six- to seven-membered non-aromatic heterocycle or a six- to seven-membered aromatic heterocycle;

R_7 is -H, -C_1-C_{10} alkyl, or -C_1-C_{10} alkoxy;

R_8 and R_9 are each independently -H, -halogen, -CN, -NH_2, -NO_2, -COOH, -$C(O)NH_2$, -SH, -$S(O)NH_2$, -$S(O)_2NH_2$, -C_1-C_{10} (oxy)alkyl, -C_1-C_{10} alkyl, -C_1-C_{10} alkoxy, -C_1-C_{10} (hydroxy)alkyl, -C_1-C_{10} (amino)alkyl, -C_1-C_{10} (halo)alkyl, -C_2-C_{10} alkenyl, -C_2-C_{10} alkynyl, -(C_3-C_7) cycloalkyl, -aryl, -C_1-C_{10} (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, -CH_2OR_{11}, -OCR_{11}, -$OC(O)R_{11}$, -$C(O)R_{11}$, -$OC(O)OR_{11}$, -$OC(O)NR_{11}$, -$C(O)OR_{11}$, -$C(O)NR_{11}$, -$OP(O)(OR_{11})_2$, -SR_{11}, -SOR_{11}, -$S(O)_2R_{11}$, -$S(O)_2NHR_{11}$, -$NHSR_{11}$, -$NHSOR_{11}$, or -$NHS(O)_2R_{11}$;

R_{10} is -H, -C_1-C_{10} alkyl, -C_3-C_7 cycloalkyl, -$C(O)C_1$-C_{10} alkyl, -C_1-C_{10} (oxy)alkyl, -$C(O)NH_2$, -$C(O)NHR_{12}$, or -aryl;

R_{11} is -H, -C_1-C_{10} alkyl, -(C_3-C_7) cycloalkyl, -C_1-C_{10} (halo)alkyl, -aryl, -C_2-C_{10} alkenyl, -C_2-C_{10} alkynyl, -C_1-C_{10} (aryl)alkyl, -C_2-C_{10} (aryl)alkenyl, -C_2-C_{10} (aryl)alkynyl, -C_1-C_{10} (hydroxy)alkyl, -C_1-C_{10} alkoxy, -C_1-C_{10} (amino)alkyl,

a -(C_3-C_7) cycloalkyl unsubstituted or substituted with one or more -C_1-C_{10} alkyl,

a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more -C_1-C_{10} alkyl, or

a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more -C_1-C_{10} alkyl, -C_2-C_{10} alkenyl, or -C_2-C_{10} alkynyl;

R_{12} is C_1-C_{10} alkyl; and

each halogen is independently -F, -Cl, -Br or -I;

with the proviso that the compound of Formula (I) is not:



10-Hydroxy-6-methoxy-1,1,4a,7-tetramethyl-1H,4aH-phenanthrene-2,9-dione; or



10-Hydroxy-7-hydroxymethyl-6-methoxy-1,1,4a-trimethyl-1H,4aH-phenanthrene-2,9-dione, or a pharmaceutically acceptable salt thereof.

2. A compound of the formula:



;



;



;

or a pharmaceutically acceptable salt thereof, the compound or pharmaceutically acceptable salt thereof being in isolated and purified form.

3. A compound of the formula:



;



;



;

or a pharmaceutically acceptable salt thereof, the compound or pharmaceutically acceptable salt thereof being in isolated and purified form.

4. The compound or pharmaceutically acceptable salt of the compound of claim 1, wherein

Q_1 and Q_2 and Q_3 are oxygen;

R_1 and R_2 are C_1-C_{10} alkyl;

R_8 and R_9 are H;

R_7 is C_1-C_{10} alkyl;

R_3 and R_6 are H; and

R_4 and R_5 are independently C_1-C_{10} alkyl, C_1-C_{10} alkoxy, or C_1-C_{10} (hydroxy)alkyl.

5. A compound having the structure:



;





;



;



; or



.

6. The compound of claim 1, having the structure:



;



;



;



;



;



;



;



;



;



;



;



;







or a pharmaceutically acceptable salt thereof.

7. A compound having the Formula (II):



(II)

or a pharmaceutically acceptable salt thereof, wherein:

Q_1 and Q_2 are independently =O, =S, =NH or =N-NHR, where R is -H, -C_1-C_{10} alkyl, or -aryl;

Q_3 is -O-, -S-, or -N(H)-;

R_1 and R_2 are independently -H, -halogen, -amino, -C_1-C_{10} alkyl, -C_1-C_{10} alkoxy, -C_1-C_{10} (hydroxy)alkyl, -C_1-C_{10} (amino)alkyl, -C_1-C_{10} (halo)alkyl, -C_2-C_{10} alkenyl, -C_2-C_{10} alkynyl, (C_3-C_7) cycloalkyl, -aryl, C_1-C_{10} (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R_1, R_2 and the carbon atom to which they are both attached are taken together to form a (C_3-C_7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;

A is N or CR_3; B is N or CR_4; D is N or CR_5; E is N or CR_6, at least one of A, B, D and E being CR_3, CR_4, CR_5 or CR_6, respectively;

each R_3, R_4, R_5 and R_6 is independently -H, -halogen, -CN, $-NH_2$, $-NO_2$, -COOH, $-C(O)NH_2$, -SH, $-S(O)NH_2$, $-S(O)_2NH_2$, $-C_1$-C_{10} (oxy)alkyl, $-C_1$-C_{10} alkyl, $-C_1$-C_{10} alkoxy, $-C_1$-C_{10} (hydroxy)alkyl, $-C_1$-C_{10} (amino)alkyl, $-C_1$-C_{10} (halo)alkyl, $-C_2$-C_{10} alkenyl, $-C_2$-C_{10} alkynyl, $-(C_3$-$C_7)$ cycloalkyl, -aryl, $-C_1$-C_{10} (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, $-CH_2OR_{11}$, $-OCH_2OR_{11}$, $-OC(O)R_{11}$, $-C(O)R_{11}$, $-OC(O)OR_{11}$, $-OC(O)NR_{11}$, $-C(O)OR_{11}$, $-C(O)NR_{11}$, $-OP(O)(OR_{11})_2$, $-SR_{11}$, $-S(O)_2NHR_{11}$, $-SOR_{11}$, $-S(O)_2R_{11}$, $-NHC(O)R_{11}$, $-NHSOR_{11}$, or $NHS(O)_2R_{11}$; or

R_3 and R_4 and the carbon atoms to which they are attached are taken together to form a $(C_3$-$C_7)$ cycloalkenyl group, a five- to seven-membered non-aromatic heterocycle, or a five- to seven-membered aromatic heterocycle; or

R_5 and R_6 and the carbon atoms to which they are attached are taken together to form a $(C_3$-$C_7)$ cycloalkenyl group, a five- to seven-membered non-aromatic heterocycle, or a five- to seven-membered aromatic heterocycle; or

R_4 and R_5 and the carbon atoms to which they are attached are taken together to form a $(C_3$-$C_7)$ cycloalkenyl group, a non-oxygen-containing five-membered non-aromatic heterocycle, a non-oxygen-containing five-membered aromatic heterocycle, a six- to seven-membered non-aromatic heterocycle or a six- to seven-membered aromatic heterocycle;

R_7 is -H, $-C_1$-C_{10} alkyl, or $-C_1$-C_{10} alkoxy;

R_8 and R_9 are each independently -H, -halogen, -CN, $-NH_2$, $-NO_2$, -COOH, $-C(O)NH_2$, -SH, $-S(O)NH_2$, $-S(O)_2NH_2$, $-C_1$-C_{10} (oxy)alkyl, $-C_1$-C_{10} alkyl, $-C_1$-C_{10} alkoxy, $-C_1$-C_{10} (hydroxy)alkyl, $-C_1$-C_{10} (amino)alkyl, $-C_1$-C_{10} (halo)alkyl, $-C_2$-C_{10} alkenyl, $-C_2$-C_{10} alkynyl, $-(C_3$-$C_7)$ cycloalkyl, -aryl, $-C_1$-C_{10} (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, $-CH_2OR_{11}$, $-OCR_{11}$, $-OC(O)R_{11}$, $-C(O)R_{11}$, $-OC(O)OR_{11}$, $-OC(O)NR_{11}$, $-C(O)OR_{11}$, $-C(O)NR_{11}$, $-OP(O)(OR_{11})_2$, $-SR_{11}$, $-SOR_{11}$, $-S(O)_2R_{11}$, $-S(O)_2NHR_{11}$, $-NHSR_{11}$, $-NHSOR_{11}$, or $-NHS(O)_2R_{11}$;

R_{10} is -H, $-C_1$-C_{10} alkyl, $-C_3$-C_7 cycloalkyl, $-C(O)C_1$-C_{10} alkyl, $-C_1$-C_{10} (oxy)alkyl, $-C(O)NH_2$, $-C(O)NHR_{12}$, or -aryl;

R_{11} is -H, -C_1-C_{10} alkyl, -(C_3-C_7) cycloalkyl, -C_1-C_{10} (halo)alkyl, -aryl, -C_2-C_{10} alkenyl, -C_2-C_{10} alkynyl, -C_1-C_{10} (aryl)alkyl, -C_2-C_{10} (aryl)alkenyl, -C_2-C_{10} (aryl)alkynyl, -C_1-C_{10} (hydroxy)alkyl, -C_1-C_{10} alkoxy, -C_1-C_{10} (amino)alkyl,

a -(C_3-C_7) cycloalkyl unsubstituted or substituted with one or more -C_1-C_{10} alkyl,

a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more -C_1-C_{10} alkyl, or

a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more -C_1-C_{10} alkyl, -C_2-C_{10} alkenyl, or -C_2-C_{10} alkynyl;

R_{12} is C_1-C_{10} alkyl; and

each halogen is independently -F, -Cl, -Br or -I.

8. A compound having the Formula (III):



(III)

or a pharmaceutically acceptable salt thereof, wherein:

Q_1, Q_2 and Q_3 are independently =O, =S, =NH or =N-NHR, where R is -H, -C_1-C_{10} alkyl, or -aryl;

R_1 and R_2 are independently -H, -halogen, -amino, -C_1-C_{10} alkyl, -C_1-C_{10} alkoxy, -C_1-C_{10} (hydroxy)alkyl, -C_1-C_{10} (amino)alkyl, -C_1-C_{10} (halo)alkyl, -C_2-C_{10} alkenyl, -C_2-C_{10} alkynyl, (C_3-C_7) cycloalkyl, -aryl, C_1-C_{10} (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R_1, R_2 and the carbon atom to which they are both attached are taken together to form a (C_3-C_7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;

A is N or CR_3; B is N or CR_4; D is N or CR_5; E is N or CR_6, at least one of A, B, D and E being CR_3, CR_4, CR_5 or CR_6, respectively;

each R_3, R_4, R_5 and R_6 is independently -H, -halogen, -CN, $-NH_2$, $-NO_2$, -COOH, $-C(O)NH_2$, -SH, $-S(O)NH_2$, $-S(O)_2NH_2$, $-C_1$-C_{10} (oxy)alkyl, $-C_1$-C_{10} alkyl, $-C_1$-C_{10} alkoxy, $-C_1$-C_{10} (hydroxy)alkyl, $-C_1$-C_{10} (amino)alkyl, $-C_1$-C_{10} (halo)alkyl, $-C_2$-C_{10} alkenyl, $-C_2$-C_{10} alkynyl, $-(C_3$-$C_7)$ cycloalkyl, -aryl, $-C_1$-C_{10} (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, $-CH_2OR_{11}$, $-OCH_2OR_{11}$, $-OC(O)R_{11}$, $-C(O)R_{11}$, $-OC(O)OR_{11}$, $-OC(O)NR_{11}$, $-C(O)OR_{11}$, $-C(O)NR_{11}$, $-OP(O)(OR_{11})_2$, $-SR_{11}$, $-S(O)_2NHR_{11}$, $-SOR_{11}$, $-S(O)_2R_{11}$, $-NHC(O)R_{11}$, $-NHSOR_{11}$, or $NHS(O)_2R_{11}$; or

R_3 and R_4 and the carbon atoms to which they are attached are taken together to form a $(C_3$-$C_7)$ cycloalkenyl group, a five- to seven-membered non-aromatic heterocycle, or a five- to seven-membered aromatic heterocycle; or

R_5 and R_6 and the carbon atoms to which they are attached are taken together to form a $(C_3$-$C_7)$ cycloalkenyl group, a five- to seven-membered non-aromatic heterocycle, or a five- to seven-membered aromatic heterocycle; or

R_4 and R_5 and the carbon atoms to which they are attached are taken together to form a $(C_3$-$C_7)$ cycloalkenyl group, a non-oxygen-containing five-membered non-aromatic heterocycle, a non-oxygen-containing five-membered aromatic heterocycle, a six- to seven-membered non-aromatic heterocycle or a six- to seven-membered aromatic heterocycle;

R_7 is -H, $-C_1$-C_{10} alkyl, or $-C_1$-C_{10} alkoxy;

R_8 and R_9 are each independently -H, -halogen, -CN, $-NH_2$, $-NO_2$, -COOH, $-C(O)NH_2$, -SH, $-S(O)NH_2$, $-S(O)_2NH_2$, $-C_1$-C_{10} (oxy)alkyl, $-C_1$-C_{10} alkyl, $-C_1$-C_{10} alkoxy, $-C_1$-C_{10} (hydroxy)alkyl, $-C_1$-C_{10} (amino)alkyl, $-C_1$-C_{10} (halo)alkyl, $-C_2$-C_{10} alkenyl, $-C_2$-C_{10} alkynyl, $-(C_3$-$C_7)$ cycloalkyl, -aryl, $-C_1$-C_{10} (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, $-CH_2OR_{11}$, $-OCR_{11}$, $-OC(O)R_{11}$, $-C(O)R_{11}$, $-OC(O)OR_{11}$, $-OC(O)NR_{11}$, $-C(O)OR_{11}$, $-C(O)NR_{11}$, $-OP(O)(OR_{11})_2$, $-SR_{11}$, $-SOR_{11}$, $-S(O)_2R_{11}$, $-S(O)_2NHR_{11}$, $-NHSR_{11}$, $-NHSOR_{11}$, or $-NHS(O)_2R_{11}$;

R_{11} is -H, $-C_1$-C_{10} alkyl, $-(C_3$-$C_7)$ cycloalkyl, $-C_1$-C_{10} (halo)alkyl, -aryl, $-C_2$-C_{10} alkenyl, $-C_2$-C_{10} alkynyl, $-C_1$-C_{10} (aryl)alkyl, $-C_2$-C_{10} (aryl)alkenyl, $-C_2$-C_{10} (aryl)alkynyl, $-C_1$-C_{10}(hydroxy)alkyl, $-C_1$-C_{10} alkoxy, $-C_1$-C_{10} (amino)alkyl,

a -(C_3-C_7) cycloalkyl unsubstituted or substituted with one or more -C_1-C_{10} alkyl,

a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more -C_1-C_{10} alkyl, or

a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more -C_1-C_{10} alkyl, -C_2-C_{10} alkenyl, or -C_2-C_{10} alkynyl;

R_{12} is C_1-C_{10} alkyl; and

each halogen is independently -F, -Cl, -Br or -I.

9. The compound of claim 8 having the formula:



;



;



;

or a pharmaceutically acceptable salt thereof.

10. A compound having the Formula (IV):



(IV)

or a pharmaceutically acceptable salt thereof, wherein:

Q_1, Q_2 and Q_3 are independently =O, =S, =NH or =N-NHR, where R is -H, -C_1-C_{10} alkyl, or -aryl;

R_1 and R_2 are independently -H, -halogen, -amino, -C_1-C_{10} alkyl, -C_1-C_{10} alkoxy, -C_1-C_{10} (hydroxy)alkyl, -C_1-C_{10} (amino)alkyl, -C_1-C_{10} (halo)alkyl, -C_2-C_{10} alkenyl, -C_2-C_{10} alkynyl, (C_3-C_7) cycloalkyl, -aryl, C_1-C_{10} (aryl)alkyl, or three- to seven-membered non-aromatic heterocycle, or R_1, R_2 and the carbon atom to which they are both attached are taken together to form a (C_3-C_7) cycloalkyl group or a three- to seven-membered non-aromatic heterocycle;

A is N or CR_3; B is N or CR_4; D is N or CR_5; E is N or CR_6, at least one of A, B, D and E being CR_3, CR_4, CR_5 or CR_6, respectively;

each R_3, R_4, R_5 and R_6 is independently -H, -halogen, -CN, -NH_2, -NO_2, -COOH, -$C(O)NH_2$, -SH, -$S(O)NH_2$, -$S(O)_2NH_2$, -C_1-C_{10} (oxy)alkyl, -C_1-C_{10} alkyl, -C_1-C_{10} alkoxy, -C_1-C_{10} (hydroxy)alkyl, -C_1-C_{10} (amino)alkyl, -C_1-C_{10} (halo)alkyl, -C_2-C_{10} alkenyl, -C_2-C_{10} alkynyl, -(C_3-C_7) cycloalkyl, -aryl, -C_1-C_{10} (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, -CH_2OR_{11}, -OCH_2OR_{11}, -$OC(O)R_{11}$, -$C(O)R_{11}$, -$OC(O)OR_{11}$, -$OC(O)NR_{11}$, -$C(O)OR_{11}$, -$C(O)NR_{11}$, -$OP(O)(OR_{11})_2$, -SR_{11}, -$S(O)_2NHR_{11}$, -SOR_{11}, -$S(O)_2R_{11}$, -$NHC(O)R_{11}$, -$NHSOR_{11}$, or $NHS(O)_2R_{11}$; or

R_3 and R_4 and the carbon atoms to which they are attached are taken together to form a (C_3-C_7) cycloalkenyl group, a five- to seven-membered non-aromatic heterocycle, or a five- to seven-membered aromatic heterocycle; or

R_5 and R_6 and the carbon atoms to which they are attached are taken together to form a (C_3-C_7) cycloalkenyl group, a five- to seven-membered non-aromatic heterocycle, or a five- to seven-membered aromatic heterocycle; or

R_4 and R_5 and the carbon atoms to which they are attached are taken together to form a (C_3-C_7) cycloalkenyl group, a non-oxygen-containing five-membered non-aromatic heterocycle, a non-oxygen-containing five-membered aromatic heterocycle, a six- to seven-membered non-aromatic heterocycle or a six- to seven-membered aromatic heterocycle;

R_7 is -H, -C_1-C_{10} alkyl, or -C_1-C_{10} alkoxy;

R_8 and R_9 are each independently -H, -halogen, -CN, -NH_2, -NO_2, -COOH, -$C(O)NH_2$, -SH, -$S(O)NH_2$, -$S(O)_2NH_2$, -C_1-C_{10} (oxy)alkyl, -C_1-C_{10} alkyl, -C_1-C_{10} alkoxy, -C_1-C_{10} (hydroxy)alkyl, -C_1-C_{10} (amino)alkyl, -C_1-C_{10} (halo)alkyl, -C_2-C_{10} alkenyl, -C_2-C_{10} alkynyl, -(C_3-C_7) cycloalkyl, -aryl, -C_1-C_{10} (aryl)alkyl, three- to seven-membered non-aromatic heterocycle, five- to seven-membered aromatic heterocycle, -CH_2OR_{11}, -OCR_{11}, -$OC(O)R_{11}$, -$C(O)R_{11}$, -$OC(O)OR_{11}$, -$OC(O)NR_{11}$, -$C(O)OR_{11}$, -$C(O)NR_{11}$, -$OP(O)(OR_{11})_2$, -SR_{11}, -SOR_{11}, -$S(O)_2R_{11}$, -$S(O)_2NHR_{11}$, -$NHSR_{11}$, -$NHSOR_{11}$, or -$NHS(O)_2R_{11}$;

R_{11} is -H, -C_1-C_{10} alkyl, -(C_3-C_7) cycloalkyl, -C_1-C_{10} (halo)alkyl, -aryl, -C_2-C_{10} alkenyl, -C_2-C_{10} alkynyl, -C_1-C_{10} (aryl)alkyl, -C_2-C_{10} (aryl)alkenyl, -C_2-C_{10} (aryl)alkynyl, -C_1-C_{10} (hydroxy)alkyl, -C_1-C_{10} alkoxy, -C_1-C_{10} (amino)alkyl,

a -(C_3-C_7) cycloalkyl unsubstituted or substituted with one or more -C_1-C_{10} alkyl,

a three- to seven-membered non-aromatic heterocycle unsubstituted or substituted with one or more -C_1-C_{10} alkyl, or

a three- to seven-membered aromatic heterocycle unsubstituted or substituted with one or more -C_1-C_{10} alkyl, -C_2-C_{10} alkenyl, or -C_2-C_{10} alkynyl;

R_{12} is C_1-C_{10} alkyl; and

each halogen is independently -F, -Cl, -Br or -I.

11-65. (Canceled)

66. A composition comprising an effective amount of the compound or pharmaceutically acceptable salt of the compound of claim 1 and a pharmaceutically acceptable carrier.

67. A composition comprising an effective amount of the compound or pharmaceutically acceptable salt of the compound of claim 2 and a pharmaceutically acceptable carrier.

68. A composition comprising an effective amount of the compound or pharmaceutically acceptable salt of the compound of claim 3 and a pharmaceutically acceptable carrier.

69. A composition comprising an effective amount of the compound or pharmaceutically acceptable salt of the compound of claim 7 and a pharmaceutically acceptable carrier.

70. A composition comprising an effective amount of the compound or pharmaceutically acceptable salt of the compound of claim 8 and a pharmaceutically acceptable carrier.

71. A composition comprising an effective amount of the compound or pharmaceutically acceptable salt of the compound of claim 10 and a pharmaceutically acceptable carrier.

72-103. (Canceled)